NEW YORK – BioMérieux has received the CE mark for its new MALDI-TOF microbiology system, the Vitek MS Prime.
The company said in late April that it plans to launch the instrument in selected European and Asian markets in the second half of 2021, with a global launched planned for 2022.
Vitek MS Prime is the next generation of BioMérieux's Vitek MS platform and includes improved automation and serviceability, Francois Lacoste, executive VP of R&D, said in a statement. He added that the benchtop system "integrates seamlessly with Vitek 2 for antimicrobial susceptibility testing and Myla middleware for data integration and insights."
"We are really pleased to bring this unique system to labs during the COVID-19 pandemic, when their needs for optimal workflow and efficiency are greater than ever," said Pierre Boulud, chief operating officer of clinical operations. "Vitek MS Prime is a powerful innovation that reinforces our offer to support antimicrobial stewardship. Unique features like prioritization of urgent samples and continuous 'load and go' allow for greater efficiency and improved outcomes, which are also key in the fight against antimicrobial resistance."